Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARSCoV2 Infection: A Review of Current Evidence". Lenze EJ, Reiersen AM, Facente SN. Drugs 2022;82:353-354.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lenze EJ, Reiersen AM, Facente SN. Authors' Reply to Mazza et al.: "Fluvoxamine for the Early Treatment of SARSCoV2 Infection: A Review of Current Evidence". Drugs 2022;82:353-354.
PMID: 35150436